Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Support from DFC will help produce one billion vaccine doses by the end of 2022
This strategic collaboration will enable continued innovation in cancer care
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
Subscribe To Our Newsletter & Stay Updated